Back to Search
Start Over
Highlights of Skin Disease Education Foundation's 41st Annual Hawaii Dermatology Seminarâ„¢
- Source :
- Seminars in cutaneous medicine and surgery. 36(4S)
- Publication Year :
- 2017
-
Abstract
- New therapies, recent pathophysiological findings, and updated guidelines combined to create compelling presentations at the Skin Disease Education Foundation's 41st Annual Hawaii Dermatology Seminarâ„¢. This educational supplement summarizes the highlights of clinical sessions presented during this CME/CE conference. A growing understanding of the biology of psoriasis has facilitated the development of increasingly efficacious medications. Skin clearance used to be regarded as an impractical goal for psoriasis therapy. Now, some clinical trials of newer medications report more than half of participants attaining Psoriasis Area and Severity Index (PASI) scores of 90. Two leading investigators review the latest findings about the treatment of this condition. Recent evidence demonstrates that psoriasis and psoriatic arthritis share multiple pathological underpinnings. A T helper type 17 (Th17) lymphocyte-based pathogenesis, genes, and microbiome changes have been identified in both conditions. Many therapeutics used in psoriasis care are efficacious in psoriatic arthritis. An expert in psoriatic arthritis updates readers about this condition. Cutaneous fungal infections, including onychomycosis, pose diagnostic and treatment challenges. New topical therapies and an investigational oral agent offer expanded options for management. The American Academy of Dermatology has issued new guidelines for the treatment of acne. Appropriate antibiotic use is a prominent theme. The US Food and Drug Administration has issued a communication about the risk of unintentional injection of soft tissue fillers into facial blood vessels-including blindness. The lead author of a recent review about this topic discusses how to prevent this serious outcome. The volume of new information about pathophysiology, diagnosis, therapy, and safety challenges our ability to keep current while enabling us to improve patient care. We hope that the highlights of this seminar offer you information that can be applied to your busy practices.
- Subjects :
- medicine.medical_specialty
business.industry
Dermatology
medicine.disease
Infliximab
Etanercept
030207 dermatology & venereal diseases
03 medical and health sciences
Psoriatic arthritis
Ixekizumab
0302 clinical medicine
Psoriasis Area and Severity Index
030220 oncology & carcinogenesis
Psoriasis
medicine
Adalimumab
Surgery
Secukinumab
business
medicine.drug
Subjects
Details
- ISSN :
- 10855629
- Volume :
- 36
- Issue :
- 4S
- Database :
- OpenAIRE
- Journal :
- Seminars in cutaneous medicine and surgery
- Accession number :
- edsair.doi.dedup.....c044e4dce767fa7717267c927758cfc8